Skip to main content
HOB BIOTECH GROUP CORP.,LTD. logo

HOB BIOTECH GROUP CORP.,LTD. — Investor Relations & Filings

Ticker · 688656 ISIN · CNE100004C37 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 632 across all filing types
Latest filing 2023-03-24 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688656

About HOB BIOTECH GROUP CORP.,LTD.

http://en.hob-biotech.com/

HOB Biotech Group Corp., Ltd. specializes in the development, manufacture, and distribution of in vitro diagnostic (IVD) products, with a primary focus on allergy and autoimmune disease testing. The company provides a comprehensive range of diagnostic solutions, including enzyme-linked immunosorbent assays (ELISA), line immunoassays, and advanced chemiluminescence immunoassay (CLIA) systems. Its product portfolio covers hundreds of allergens and a wide array of autoimmune markers, catering to clinical laboratories and healthcare providers. HOB Biotech is recognized for its proprietary technology platforms that enable high-throughput, automated testing, improving diagnostic efficiency and accuracy. The company's commitment to research and development supports the continuous expansion of its diagnostic menu to address evolving clinical needs in immunology and hypersensitivity.

Recent filings

Filing Released Lang Actions
江苏浩欧博生物医药股份有限公司独立董事关于第二届董事会第二十二次会议相关事项的独立意见
Regulatory Filings
2023-03-24 Chinese
江苏浩欧博生物医药股份有限公司关于董事会秘书辞职及聘任董事会秘书的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the resignation of the current board secretary and the appointment of a new board secretary. It includes details about the individuals involved, their qualifications, and the board's approval process. There is no financial data, earnings information, or report publication mentioned. The content clearly relates to changes in the company's board or senior management positions. Therefore, this fits the category of Board/Management Information (MANG). The document length is short and focused solely on management changes, confirming this classification.
2023-03-24 Chinese
江苏浩欧博生物医药股份有限公司2022年度业绩快报公告
Earnings Release Classification · 95% confidence The document is titled as a "2022年度业绩快报公告" which translates to "2022 Annual Performance Express Report Announcement." It contains preliminary financial data for the year 2022, including revenue, profit, net income, earnings per share, and asset information. The data is explicitly stated as preliminary and unaudited, with a note that the final audited data will be in the 2022 Annual Report. The document is relatively short (2361 characters) and serves as a quick financial performance update rather than a full comprehensive report. It does not contain full financial statements or detailed analysis typical of an Interim/Quarterly Report or Annual Report. This type of document is best classified as an Earnings Release (ER), which is an initial announcement of periodic financial results with key highlights only. FY 2022
2023-02-27 Chinese
江苏浩欧博生物医药股份有限公司2022年年度业绩预减公告
Earnings Release Classification · 95% confidence The document is a 2022 annual performance forecast announcement by Jiangsu Haobo Biopharmaceutical Co., Ltd. It provides preliminary profit estimates for the full year 2022, comparing them to the previous year, and explains reasons for the expected decline. It explicitly states that the forecast has not been audited by a registered accountant and that the final audited annual report will be published later. The document is short (1373 characters) and serves as an earnings forecast or profit warning rather than a full financial report. It does not contain actual financial statements or detailed financial data, only preliminary estimates and explanations. Therefore, it fits best as an Earnings Release (ER) type, which covers initial announcements of periodic financial results or profit warnings. FY 2022
2023-01-30 Chinese
江苏浩欧博生物医药股份有限公司关于使用部分闲置募集资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Jiangsu Haoubo Biopharmaceutical Co., Ltd. regarding the use of part of idle raised funds for cash management. It details the board's approval, investment purpose, product types, risk control measures, and opinions from the supervisory board, independent directors, and the sponsoring institution. The document is relatively short (3786 characters) and focuses on the company's financing activities related to the use of idle raised funds, not on financial results or comprehensive reports. It is not a full financial report, audit report, or earnings release. It is an update on capital/financing activities, specifically the use of idle raised funds for cash management. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2023-01-18 Chinese
江苏浩欧博生物医药股份有限公司第二届监事会第十七次会议决议公告
Board/Management Information Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of Jiangsu Haobo Biomedical Co., Ltd. It details the meeting date, attendance, and the resolutions passed, including the use of idle raised funds for cash management and amendments to the internal audit system. It does not contain financial statements or detailed financial data but rather reports on board-level decisions and approvals. The document is not an annual or interim report, audit report, or earnings release. It is not a call transcript or investor presentation. It is a formal announcement of board/management decisions, specifically from the supervisory board, which fits the category of Board/Management Information (MANG). The document length is short and focused on meeting resolutions, not a report publication announcement or regulatory filing. Therefore, the best classification is MANG with high confidence.
2023-01-18 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.